Neurogene Inc
NGNE21.765USD
-0.015-0.07%
交易中 （美东）报价延迟15分钟
324.94M总市值
亏损市盈率 TTM
关于 Neurogene Inc 公司
Neurogene Inc. 是一家临床阶段的生物技术公司。该公司通过其专有的转基因调控技术“通过结构调节表达衰减”（EXACT），正在构建一个基因药物产品组合，用于治疗罕见的神经系统疾病，这些疾病具有大量未满足的需求，而传统基因疗法无法满足这些需求。其临床阶段项目 NGN-401 利用 EXACT 平台，该平台正在开发用于治疗雷特综合征，这种疾病的患者群体具有大量未满足的需求，最终会发展为严重的神经和身体损伤以及过早死亡。NGN-401 正在一项 1/2 期开放标签、多中心临床试验中对患有雷特综合征的女童患者进行评估，该试验评估了使用一次性脑室 (ICV) 程序输送两剂 NGN-401 的安全性、耐受性和有效性。该公司还在开发用于治疗 CLN5 巴顿病的 NGN-101。
公司简介
公司代码NGNE
公司名称Neurogene Inc
上市日期Mar 07, 2014
CEODr. Rachel L. McMinn, Ph.D.
员工数量107
证券类型Ordinary Share
年结日Mar 07
公司地址535 W 24Th Street
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编10011
电话18772375020
网址https://www.neurogene.com/
公司代码NGNE
上市日期Mar 07, 2014
CEODr. Rachel L. McMinn, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
Dr. Rachel L. McMinn, Ph.D.
Dr. Rachel L. McMinn, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Christine Mikail Cvijic, J.D.
Ms. Christine Mikail Cvijic, J.D.
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
名称
名称/职务
职务
持股
持股变动
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Samsara BioCapital, LLC
12.04%
Baker Bros. Advisors LP
10.42%
RTW Investments L.P.
9.46%
Redmile Group, LLC
9.17%
Casdin Capital, LLC
9.08%
Other
49.83%
持股股东
持股股东
占比
Samsara BioCapital, LLC
12.04%
Baker Bros. Advisors LP
10.42%
RTW Investments L.P.
9.46%
Redmile Group, LLC
9.17%
Casdin Capital, LLC
9.08%
Other
49.83%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
39.97%
Hedge Fund
39.66%
Investment Advisor
18.66%
Venture Capital
12.04%
Individual Investor
9.23%
Research Firm
5.10%
Bank and Trust
0.13%
Pension Fund
0.07%
Insurance Company
0.02%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
207
17.81M
124.87%
-2.19M
2025Q1
216
18.11M
126.54%
-1.93M
2024Q4
211
17.68M
118.99%
+934.89K
2024Q3
193
15.29M
117.57%
+50.95K
2024Q2
185
14.71M
113.65%
+656.15K
2024Q1
190
13.87M
122.85%
+4.51M
2023Q4
186
10.89M
99.88%
+9.09M
2023Q3
208
1.31M
59.57%
-490.20K
2023Q2
215
1.27M
59.11%
-309.84K
2023Q1
219
1.22M
57.26%
-516.47K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Samsara BioCapital, LLC
1.72M
12.04%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
1.49M
10.42%
+811.75K
+120.36%
Mar 31, 2025
RTW Investments L.P.
1.35M
9.46%
-1.60K
-0.12%
Mar 31, 2025
Redmile Group, LLC
1.31M
9.17%
-11.70K
-0.89%
Mar 31, 2025
Casdin Capital, LLC
1.30M
9.08%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
1.27M
8.91%
--
--
Mar 31, 2025
McMinn (Rachel L. Ph.D.)
1.25M
8.77%
-71.49K
-5.41%
Apr 16, 2025
BlackRock Institutional Trust Company, N.A.
946.32K
6.64%
+55.48K
+6.23%
Mar 31, 2025
Commodore Capital LP
925.00K
6.49%
+125.00K
+15.63%
Mar 31, 2025
The Vanguard Group, Inc.
617.93K
4.33%
+49.92K
+8.79%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.66%
iShares Neuroscience and Healthcare ETF
0.43%
Franklin Genomic Advancements ETF
0.14%
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.66%
iShares Neuroscience and Healthcare ETF
占比0.43%
Franklin Genomic Advancements ETF
占比0.14%
Fidelity Enhanced Small Cap ETF
占比0.04%
iShares Micro-Cap ETF
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
iShares Biotechnology ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
公告日期
类型
比率
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
